NCT04660097 2026-04-08
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Completed
Clinical Trials
3 trialsNCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
NCT03059797 2019-05-16
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed